Free Trial

Phil Nadeau Analyst Performance

Analyst at TD Cowen

Phil Nadeau is a stock analyst at TD Cowen in the medical sector, covering 23 publicly traded companies. Over the past year, Phil Nadeau has issued 4 stock ratings, including and buy recommendations. While full access to Phil Nadeau's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Phil Nadeau's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
108 Last 11 Years
Buy Recommendations
77.78% 84 Buy Ratings
Companies Covered
23 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy77.8%84 ratings
Hold22.2%24 ratings
Sell0.0%0 ratings

Out of 108 total stock ratings issued by Phil Nadeau at TD Cowen, the majority (77.8%) have been Buy recommendations, followed by 22.2% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
23 companies

Phil Nadeau, an analyst at TD Cowen, currently covers 23 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
23 companies
100.0%

Phil Nadeau of TD Cowen specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
16 companies
69.6%
MED - DRUGS
3 companies
13.0%
PHARMACEUTICAL PREPARATIONS
3 companies
13.0%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company
4.3%

Phil Nadeau's Ratings History at TD Cowen

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Surrozen, Inc. stock logo
SRZN
Surrozen
4/21/2026Initiated Coverage$32.25Buy
Biogen Inc. stock logo
BIIB
Biogen
2/9/2026Boost Price Target$201.18$215.00Buy
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
12/5/2025Boost Price Target$156.58$200.00Buy
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
10/31/2025Lower Price Target$21.03$45.00Buy